Rapid Dose Therapeutics Corp (TSE:DOSE)
:DOSE
Want to see TSE:DOSE full AI Analyst Report?
Top Page
Rapid Dose Therapeutics Corp
(DOSE)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.09
▼(-35.00% Downside)
Action:Reiterated
Date:03/12/26
The score is mainly held down by weak financial performance—large ongoing losses, negative equity, and continued cash burn—indicating elevated funding and execution risk. Technicals also reflect a clear downtrend despite oversold conditions. Valuation provides limited support due to negative earnings and no indicated dividend yield.
Positive Factors
Proprietary oral thin‑film platform
The company’s owned quick-dissolve oral film technology is a durable competitive asset. As an enabling delivery platform it can generate formulation and licensing revenue, create switching costs for partners, and support cross-market applications in pharma and consumer health over multiple product cycles.
Negative Factors
Negative shareholders' equity and leverage
A deficit equity position combined with material debt raises solvency and liquidity risk. This structural balance-sheet weakness limits financial flexibility, increases default or covenant risk, and makes future funding more dilutive or expensive, constraining long-term investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oral thin‑film platform
The company’s owned quick-dissolve oral film technology is a durable competitive asset. As an enabling delivery platform it can generate formulation and licensing revenue, create switching costs for partners, and support cross-market applications in pharma and consumer health over multiple product cycles.
Read all positive factors
Rapid Dose Therapeutics Corp (DOSE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$14.51M
Dividend YieldN/A
Average Volume (3M)36.09K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue Growth72.84%
EPS Growth29.98%
CountryCA
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding131,886,760
10 Day Avg. Volume35,351
30 Day Avg. Volume36,089
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)-5.82
Price to Sales (P/S)18.01
P/FCF Ratio-8.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rapid Dose Therapeutics Corp Business Overview & Revenue Model
Company Description
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rap...
How the Company Makes Money
null...
Rapid Dose Therapeutics Corp Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | May 2024 | May 2023 | Nov 2022 | Feb 2021 | Feb 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.78M | 2.09M | 1.02M | 1.75M | 755.20K | 101.50K |
| Gross Profit | 829.37K | 1.18M | 563.41K | 1.34M | 699.85K | 37.34K |
| EBITDA | -2.62M | -3.93M | -3.02M | -7.59M | -987.00K | -7.37M |
| Net Income | -4.37M | -5.40M | -4.31M | -8.49M | -1.80M | -7.96M |
Balance Sheet | ||||||
| Total Assets | 3.79M | 1.63M | 1.89M | 3.07M | 3.83M | 4.29M |
| Cash, Cash Equivalents and Short-Term Investments | 109.16K | 20.72K | 161.06K | 34.44K | 70.26K | 3.47K |
| Total Debt | 8.28M | 2.61M | 2.45M | 1.43M | 2.06M | 1.22M |
| Total Liabilities | 10.43M | 6.84M | 5.04M | 2.82M | 5.41M | 4.44M |
| Stockholders Equity | -6.65M | -5.21M | -3.16M | 251.56K | -1.58M | -147.78K |
Cash Flow | ||||||
| Free Cash Flow | -3.46M | -1.15M | -2.29M | -3.04M | -1.63M | -4.26M |
| Operating Cash Flow | -906.04K | -1.15M | -2.29M | -3.00M | -1.62M | -3.03M |
| Investing Cash Flow | -2.55M | -5.74K | 0.00 | 1.85M | -9.12K | 530.46K |
| Financing Cash Flow | 3.49M | 1.01M | 2.43M | 1.13M | 1.65M | 1.24M |
Rapid Dose Therapeutics Corp Technical Analysis
Positive
0.14
Price Trends
0.10
Positive
0.12
Negative
0.14
Negative
Market Momentum
>-0.01
Negative
55.53
Neutral
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.53 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DOSE.
Rapid Dose Therapeutics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$13.79M | 0.67 | ― | ― | ― | ― | |
46 Neutral | C$36.47M | -0.31 | -221.75% | ― | ― | 44.28% | |
42 Neutral | C$14.51M | -3.16 | 75.85% | ― | 72.84% | 29.98% | |
41 Neutral | C$10.88M | -2.33 | ― | ― | ― | 28.10% |
* Healthcare Sector Average
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.12
-51.11%
TSE:BCT
BriaCell Therapeutics
4.56
-41.64
-90.13%
TSE:HEM
Hemostemix
0.06
-0.06
-50.00%
TSE:BLAB
Britannia Life Sciences Inc
0.09
0.03
41.67%
TSE:TELI
Telescope Innovations Corp
0.64
0.35
116.95%
Rapid Dose Therapeutics Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rapid Dose Wins Key Indian Patent for QuickStrip Nicotine Oral Film
Positive
Mar 5, 2026
Rapid Dose Therapeutics has secured an Indian patent for its QuickStrip nicotine bilayer oral film, developed with Aavishkar Oral Strips, covering a controlled-release, fast-absorbing oral strip and its proprietary manufacturing process. The prote...
Business Operations and StrategyProduct-Related Announcements
Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform
Positive
Feb 23, 2026
Rapid Dose Therapeutics has provided an update on cannabinoid-focused research and clinical work involving its QuickStrip oral thin film platform. Independent researchers at the University of Regina and the University of Saskatchewan, supported by...
Business Operations and StrategyDelistings and Listing Changes
Rapid Dose Therapeutics Lists on U.S. OTCQB to Broaden Investor Access
Positive
Feb 11, 2026
Rapid Dose Therapeutics Corp., a Canadian biotechnology company specializing in oral thin film drug delivery, is building its QuickStrip portfolio to serve pharmaceutical, nutraceutical and vaccine applications that require rapid and discreet admi...
Business Operations and StrategyProduct-Related Announcements
Rapid Dose Therapeutics Enters Brazil’s Medical Cannabis Market With QuickStrip Launch
Positive
Feb 10, 2026
Rapid Dose Therapeutics has launched its co-branded QuickStrip medical cannabis oral thin film in Brazil after securing regulatory approval from Brazil’s health regulator ANVISA for sublingual and buccal administration formats. The product, ...
Business Operations and StrategyPrivate Placements and Financing
Rapid Dose Therapeutics Pays Convertible Note Interest in Shares
Neutral
Jan 6, 2026
Rapid Dose Therapeutics Corp. will issue 362,708 common shares to holders of its secured convertible notes to satisfy approximately $47,154 in quarterly interest accrued as of December 31, 2025, with issuance expected by January 15, 2026. The inte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.